Disease Clusters?

Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.

← Back to all clusters

Cluster 21

19 diseases · 33 shared-gene connections
19 Diseases
1,872 Unique genes
0.057 Avg. similarity score
Breast neoplasms Most-connected disease (9 links)
Log in to save this analysis

Save This Analysis

Disease Searched: Breast neoplasms Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details · click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) · drag a node to pin it in place · scroll/pinch to zoom.

Member diseases (most connected first ‐ the cluster's core)

Disease ⇵ Connections in cluster ⇵ Significant partners ⇵ Curated genes ⇵
Breast neoplasms 9 9 529
Lung neoplasms 8 8 254
Stomach neoplasms 7 7 306
Liver neoplasms 6 6 152
Urinary bladder neoplasms 6 6 142
Non-small-cell lung carcinoma 5 5 142
Prostatic neoplasms 5 5 627
Neuroblastoma 4 4 151
Carcinoma 3 3 165
Mesothelioma 2 2 145
Pulmonary agenesis 2 2 1
Uterine neoplasms 2 2 38
Cerebellar ataxia, brain abnormalities, and cardiac conduction defects 1 1 1
Colobomatous macrophthalmia microcornea syndrome 1 1 1
Diffuse lymphatic malformation 1 1 1
Hypotrichosis and recurrent skin vesicles 1 1 1
Intellectual developmental disorder seizures polymicrogyria 1 1 1
Isobutyryl-coa dehydrogenase deficiency 1 1 1
Retinitis pigmentosa, hearing loss, premature aging, short stature, facial dysmorphism syndrome 1 1 1

Top shared genes (genes linked to 2+ member diseases ‐ top 100 shown, download for all)

Gene ⇵ Member diseases ⇵ Linked diseases
KRAS 10 / 19 Breast neoplasms, Carcinoma, Liver neoplasms, Lung neoplasms and 6 more
TP53 10 / 19 Breast neoplasms, Carcinoma, Liver neoplasms, Lung neoplasms and 6 more
EGFR 9 / 19 Breast neoplasms, Carcinoma, Lung neoplasms, Mesothelioma and 5 more
MYC 9 / 19 Carcinoma, Liver neoplasms, Lung neoplasms, Neuroblastoma and 5 more
STAT3 9 / 19 Breast neoplasms, Carcinoma, Liver neoplasms, Lung neoplasms and 5 more
BAP1 8 / 19 Breast neoplasms, Liver neoplasms, Lung neoplasms, Mesothelioma and 4 more
CCND1 8 / 19 Breast neoplasms, Carcinoma, Liver neoplasms, Lung neoplasms and 4 more
CDKN2A 8 / 19 Breast neoplasms, Liver neoplasms, Lung neoplasms, Mesothelioma and 4 more
ESR1 8 / 19 Breast neoplasms, Carcinoma, Liver neoplasms, Lung neoplasms and 4 more
FHIT 8 / 19 Carcinoma, Liver neoplasms, Lung neoplasms, Mesothelioma and 4 more
HRAS 8 / 19 Breast neoplasms, Carcinoma, Liver neoplasms, Lung neoplasms and 4 more
TERT 8 / 19 Breast neoplasms, Liver neoplasms, Lung neoplasms, Neuroblastoma and 4 more
CDKN1B 7 / 19 Breast neoplasms, Liver neoplasms, Lung neoplasms, Mesothelioma and 3 more
GSTP1 7 / 19 Breast neoplasms, Carcinoma, Lung neoplasms, Non-small-cell lung carcinoma and 3 more
MET 7 / 19 Carcinoma, Lung neoplasms, Mesothelioma, Neuroblastoma and 3 more
SOD2 7 / 19 Breast neoplasms, Carcinoma, Mesothelioma, Non-small-cell lung carcinoma and 3 more
APC 6 / 19 Liver neoplasms, Lung neoplasms, Mesothelioma, Non-small-cell lung carcinoma and 2 more
BIRC5 6 / 19 Breast neoplasms, Lung neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms and 2 more
CDH1 6 / 19 Breast neoplasms, Carcinoma, Mesothelioma, Prostatic neoplasms and 2 more
CDKN1A 6 / 19 Liver neoplasms, Lung neoplasms, Mesothelioma, Prostatic neoplasms and 2 more
CSF3 6 / 19 Breast neoplasms, Carcinoma, Liver neoplasms, Non-small-cell lung carcinoma and 2 more
CTNNB1 6 / 19 Breast neoplasms, Liver neoplasms, Lung neoplasms, Mesothelioma and 2 more
CXCL8 6 / 19 Breast neoplasms, Mesothelioma, Non-small-cell lung carcinoma, Prostatic neoplasms and 2 more
MTHFR 6 / 19 Breast neoplasms, Lung neoplasms, Prostatic neoplasms, Stomach neoplasms and 2 more
MTOR 6 / 19 Breast neoplasms, Mesothelioma, Non-small-cell lung carcinoma, Prostatic neoplasms and 2 more
RAF1 6 / 19 Breast neoplasms, Liver neoplasms, Lung neoplasms, Mesothelioma and 2 more
TNF 6 / 19 Breast neoplasms, Liver neoplasms, Lung neoplasms, Neuroblastoma and 2 more
ARID1A 5 / 19 Breast neoplasms, Neuroblastoma, Prostatic neoplasms, Stomach neoplasms and 1 more
BCL2 5 / 19 Breast neoplasms, Carcinoma, Mesothelioma, Prostatic neoplasms and 1 more
CASP8 5 / 19 Breast neoplasms, Lung neoplasms, Non-small-cell lung carcinoma, Stomach neoplasms and 1 more
CCNH 5 / 19 Breast neoplasms, Carcinoma, Liver neoplasms, Non-small-cell lung carcinoma and 1 more
CHEK2 5 / 19 Breast neoplasms, Lung neoplasms, Neuroblastoma, Prostatic neoplasms and 1 more
CLPTM1L 5 / 19 Lung neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms, Urinary bladder neoplasms and 1 more
ERBB2 5 / 19 Breast neoplasms, Lung neoplasms, Prostatic neoplasms, Stomach neoplasms and 1 more
GSTM1 5 / 19 Liver neoplasms, Lung neoplasms, Mesothelioma, Prostatic neoplasms and 1 more
HIF1A 5 / 19 Breast neoplasms, Carcinoma, Non-small-cell lung carcinoma, Prostatic neoplasms and 1 more
HMOX1 5 / 19 Breast neoplasms, Liver neoplasms, Lung neoplasms, Prostatic neoplasms and 1 more
IL6 5 / 19 Breast neoplasms, Lung neoplasms, Mesothelioma, Prostatic neoplasms and 1 more
MMP9 5 / 19 Breast neoplasms, Neuroblastoma, Non-small-cell lung carcinoma, Prostatic neoplasms and 1 more
NAT2 5 / 19 Breast neoplasms, Liver neoplasms, Mesothelioma, Prostatic neoplasms and 1 more
NFE2L2 5 / 19 Breast neoplasms, Liver neoplasms, Lung neoplasms, Non-small-cell lung carcinoma and 1 more
PTGS2 5 / 19 Breast neoplasms, Carcinoma, Prostatic neoplasms, Stomach neoplasms and 1 more
RB1 5 / 19 Breast neoplasms, Carcinoma, Non-small-cell lung carcinoma, Prostatic neoplasms and 1 more
ABCB1 4 / 19 Breast neoplasms, Carcinoma, Neuroblastoma, Non-small-cell lung carcinoma
AHR 4 / 19 Breast neoplasms, Liver neoplasms, Prostatic neoplasms, Stomach neoplasms
AKT1 4 / 19 Breast neoplasms, Lung neoplasms, Prostatic neoplasms, Urinary bladder neoplasms
ATM 4 / 19 Breast neoplasms, Prostatic neoplasms, Stomach neoplasms, Urinary bladder neoplasms
ATP7B 4 / 19 Breast neoplasms, Carcinoma, Liver neoplasms, Prostatic neoplasms
CAT 4 / 19 Breast neoplasms, Mesothelioma, Non-small-cell lung carcinoma, Urinary bladder neoplasms
CAV1 4 / 19 Breast neoplasms, Lung neoplasms, Prostatic neoplasms, Stomach neoplasms
CYP2E1 4 / 19 Liver neoplasms, Lung neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms
DNMT1 4 / 19 Breast neoplasms, Carcinoma, Prostatic neoplasms, Stomach neoplasms
DNMT3B 4 / 19 Breast neoplasms, Carcinoma, Prostatic neoplasms, Stomach neoplasms
EFEMP1 4 / 19 Breast neoplasms, Carcinoma, Lung neoplasms, Mesothelioma
ENO1 4 / 19 Breast neoplasms, Carcinoma, Non-small-cell lung carcinoma, Stomach neoplasms
EPHX1 4 / 19 Carcinoma, Lung neoplasms, Mesothelioma, Prostatic neoplasms
ERCC1 4 / 19 Lung neoplasms, Non-small-cell lung carcinoma, Stomach neoplasms, Uterine neoplasms
ESR2 4 / 19 Breast neoplasms, Carcinoma, Prostatic neoplasms, Urinary bladder neoplasms
HES1 4 / 19 Breast neoplasms, Lung neoplasms, Non-small-cell lung carcinoma, Uterine neoplasms
IL10 4 / 19 Breast neoplasms, Lung neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms
IL1B 4 / 19 Breast neoplasms, Lung neoplasms, Neuroblastoma, Stomach neoplasms
IL2 4 / 19 Liver neoplasms, Lung neoplasms, Prostatic neoplasms, Urinary bladder neoplasms
JUN 4 / 19 Breast neoplasms, Liver neoplasms, Lung neoplasms, Stomach neoplasms
MACIR 4 / 19 Breast neoplasms, Liver neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms
MDM2 4 / 19 Breast neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms, Stomach neoplasms
MIF 4 / 19 Breast neoplasms, Carcinoma, Mesothelioma, Prostatic neoplasms
NCOR1 4 / 19 Breast neoplasms, Liver neoplasms, Prostatic neoplasms, Urinary bladder neoplasms
NDRG1 4 / 19 Breast neoplasms, Liver neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms
NOTCH2 4 / 19 Breast neoplasms, Lung neoplasms, Stomach neoplasms, Uterine neoplasms
NQO1 4 / 19 Breast neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms, Urinary bladder neoplasms
PHGDH 4 / 19 Breast neoplasms, Liver neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms
PIK3CA 4 / 19 Breast neoplasms, Lung neoplasms, Prostatic neoplasms, Stomach neoplasms
PTEN 4 / 19 Breast neoplasms, Carcinoma, Lung neoplasms, Prostatic neoplasms
PYCARD 4 / 19 Lung neoplasms, Mesothelioma, Non-small-cell lung carcinoma, Stomach neoplasms
RARB 4 / 19 Breast neoplasms, Lung neoplasms, Stomach neoplasms, Uterine neoplasms
RASSF1 4 / 19 Lung neoplasms, Mesothelioma, Non-small-cell lung carcinoma, Urinary bladder neoplasms
TGFA 4 / 19 Liver neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms, Stomach neoplasms
TNFSF10 4 / 19 Breast neoplasms, Liver neoplasms, Neuroblastoma, Prostatic neoplasms
TYMS 4 / 19 Breast neoplasms, Lung neoplasms, Prostatic neoplasms, Stomach neoplasms
VIM 4 / 19 Breast neoplasms, Carcinoma, Mesothelioma, Prostatic neoplasms
ACE 3 / 19 Lung neoplasms, Prostatic neoplasms, Stomach neoplasms
ACHE 3 / 19 Breast neoplasms, Prostatic neoplasms, Urinary bladder neoplasms
ALK 3 / 19 Breast neoplasms, Neuroblastoma, Non-small-cell lung carcinoma
ANXA2 3 / 19 Liver neoplasms, Lung neoplasms, Mesothelioma
ANXA4 3 / 19 Carcinoma, Liver neoplasms, Prostatic neoplasms
APOA1 3 / 19 Lung neoplasms, Mesothelioma, Stomach neoplasms
APOBEC3B 3 / 19 Breast neoplasms, Urinary bladder neoplasms, Uterine neoplasms
AR 3 / 19 Breast neoplasms, Lung neoplasms, Prostatic neoplasms
AREG 3 / 19 Breast neoplasms, Non-small-cell lung carcinoma, Stomach neoplasms
AURKA 3 / 19 Breast neoplasms, Neuroblastoma, Prostatic neoplasms
BCL2L1 3 / 19 Carcinoma, Lung neoplasms, Stomach neoplasms
BIRC2 3 / 19 Breast neoplasms, Neuroblastoma, Stomach neoplasms
BRAF 3 / 19 Liver neoplasms, Lung neoplasms, Prostatic neoplasms
BRCA1 3 / 19 Breast neoplasms, Carcinoma, Prostatic neoplasms
BRCA2 3 / 19 Breast neoplasms, Lung neoplasms, Prostatic neoplasms
CDH13 3 / 19 Lung neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms
CDK4 3 / 19 Breast neoplasms , Carcinoma, Stomach neoplasms
CHD6 3 / 19 Neuroblastoma, Prostatic neoplasms, Urinary bladder neoplasms
CSF2 3 / 19 Breast neoplasms, Carcinoma, Liver neoplasms
CST6 3 / 19 Breast neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms
What do these columns mean?
Connections in cluster
How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
Significant partners
How many of those links are statistically significant (FDR q < 0.05).
Curated genes
Distinct curated genes linked to that disease in GeDiPNet.
Member diseases (Top shared genes)
How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
Overlap genes (x / y)
x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
Cluster gene count
Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
Fold enrichment
Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
P-value / FDR q-value
Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
Shared genes (Pairs within this cluster)
Number of curated genes the two diseases in that row have in common.
Similarity score (Pairs within this cluster)
Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.

Enriched Pathways (why this cluster is grouped, biologically)

Pathway ⇵ Source ⇵ Overlap genes ⇵ Fold enrichment ⇵ P-value ⇵ FDR q-value ⇵
Pathways in cancer
ESR1, FGFR2, ABL1, AKT1, AKT2, ALK, APC2, AR, ARAF, BAX, BCL2, BIRC2
 KEGG 224 / 533 2.7× 2.07e-51 3.63e-47 ✓ sig.
Prostate cancer
FGFR2, AKT1, AKT2, AR, ARAF, BCL2, CCND1, CCNE1, CDKN1B, CTNNB1, E2F1, EGF
 KEGG 71 / 98 4.7× 1.48e-36 6.30e-33 ✓ sig.
Endocrine resistance
ESR1, AKT1, AKT2, ARAF, BAX, BCL2, CCND1, CDKN1B, CDKN2A, CYP2D6, DLL1, DLL4
 KEGG 63 / 99 4.1× 1.63e-27 3.55e-24 ✓ sig.
Breast cancer
ESR1, AKT1, AKT2, APC2, ARAF, BAX, BRCA1, BRCA2, CCND1, CTNNB1, DLL1, DLL4
 KEGG 79 / 148 3.4× 7.44e-27 1.45e-23 ✓ sig.
PI3K-Akt signaling pathway
FGFR2, AKT1, AKT2, AREG, ARTN, BCL2, BRCA1, CCND1, CCNE1, CDKN1B, CSF1, CSF1R
 KEGG 138 / 361 2.5× 1.25e-26 2.38e-23 ✓ sig.
Non-small cell lung cancer
AKT1, AKT2, ALK, ARAF, BAX, CCND1, CDKN2A, E2F1, EGF, EGFR, ERBB2, HRAS
 KEGG 52 / 73 4.6× 1.66e-26 3.06e-23 ✓ sig.
Proteoglycans in cancer
ESR1, AKT1, AKT2, ARAF, CAV1, CCND1, CTNNB1, EGFR, ERBB2, ERBB3, FGFR1, FLNA
 KEGG 95 / 204 3.0× 4.18e-26 7.36e-23 ✓ sig.
Bladder cancer
ARAF, CCND1, CDH1, CDKN2A, CXCL8, E2F1, EGF, EGFR, ERBB2, HRAS, KRAS, MDM2
 KEGG 37 / 41 5.8× 4.46e-26 7.72e-23 ✓ sig.
Pancreatic cancer
AKT1, AKT2, ARAF, BAX, BRCA2, CCND1, CDKN2A, E2F1, EGF, EGFR, ERBB2, KRAS
 KEGG 52 / 77 4.4× 9.30e-25 1.39e-21 ✓ sig.
Melanoma
AKT1, AKT2, ARAF, BAX, CCND1, CDH1, CDKN2A, E2F1, EGF, EGFR, FGF10, FGF3
 KEGG 50 / 73 4.4× 2.74e-24 4.00e-21 ✓ sig.
EGFR tyrosine kinase inhibitor resistance
FGFR2, AKT1, AKT2, ARAF, BAX, BCL2, EGF, EGFR, ERBB2, ERBB3, GSK3B, HRAS
 KEGG 52 / 80 4.2× 1.44e-23 1.79e-20 ✓ sig.
Hepatocellular carcinoma
AKT1, AKT2, APC2, ARAF, ARID1A, BAX, CCND1, CDKN2A, CTNNB1, E2F1, EGFR, GSK3B
 KEGG 81 / 170 3.1× 3.08e-23 3.66e-20 ✓ sig.
Gastric cancer
FGFR2, ABCB1, AKT1, AKT2, APC2, ARAF, BAX, BCL2, CCND1, CCNE1, CDH1, CDKN1B
 KEGG 75 / 150 3.2× 3.10e-23 3.66e-20 ✓ sig.
Interleukin-4 and Interleukin-13 signaling
AKT1, BCL2, BIRC5, CCND1, CXCL8, FN1, FOS, HIF1A, HMOX1, HSP90AA1, IL10, IL1B
 Reactome 61 / 108 3.6× 9.74e-23 1.10e-19 ✓ sig.
Lipid and atherosclerosis
AKT1, AKT2, BAX, BCL2, CASP7, CASP8, CD40, CXCL2, CXCL3, CXCL8, CYP1A1, DDIT3
 KEGG 93 / 216 2.8× 1.59e-22 1.77e-19 ✓ sig.

Enriched GO Terms (Biological Process, a second line of biological evidence)

GO term ⇵ GO ID ⇵ Overlap genes ⇵ Fold enrichment ⇵ P-value ⇵ FDR q-value ⇵
positive regulation of transcription by RNA polymerase II
MRTFB, AHR, ESR1, FGFR2, ABL1, ACVR1, AKT1, AR, ATM, BMP2, BMP4, BMPR2
 GO:0045944 294 / 1,208 2.4× 2.40e-51 5.29e-47 ✓ sig.
negative regulation of apoptotic process
AKT1, AKT2, ANGPTL4, ARAF, ARHGDIA, AURKA, BAG1, BARD1, BCL2, BCL2A1, BIRC2, BIRC5
 GO:0043066 171 / 524 3.3× 1.48e-47 2.49e-43 ✓ sig.
positive regulation of gene expression
ACTA2, AGR2, AKT1, AR, ATM, BMP2, BMP4, BMPR2, BRCA1, CAV1, CD74, CDH5
 GO:0010628 160 / 504 3.2× 9.18e-43 1.14e-38 ✓ sig.
positive regulation of cell population proliferation
FGFR2, ADAM10, AR, AREG, BCAR3, BCL2, BIRC5, BMP2, BMP4, CCND1, CDKN1B, CSF1
 GO:0008284 160 / 532 3.0× 1.84e-39 1.85e-35 ✓ sig.
negative regulation of transcription by RNA polymerase II
ESR1, FGFR2, AR, BMP2, BMP4, C1QBP, CASP7, CAV1, CCND1, CCNE1, CDKN2A, CTNNB1
 GO:0000122 226 / 1,002 2.3× 1.21e-33 9.07e-30 ✓ sig.
apoptotic process
AHR, CHEK2, FGFR2, ABL1, ADAR, AFP, AKT1, AKT2, AURKA, BAG1, BAX, BCL2
 GO:0006915 183 / 747 2.5× 5.65e-32 3.62e-28 ✓ sig.
positive regulation of cell migration
ACVR1, ADAM10, AKT1, AKT2, ATM, BMP2, BMP4, CASP8, CAV1, CDH5, CLDN1, CLDN4
 GO:0030335 100 / 292 3.4× 5.49e-30 3.02e-26 ✓ sig.
negative regulation of cell population proliferation
ADAMTS1, AR, BAP1, BAX, BCHE, BCL2, BMP2, BMP4, BMPR2, CAV1, CDH5, CDKN1B
 GO:0008285 128 / 444 2.9× 1.13e-29 6.03e-26 ✓ sig.
positive regulation of MAPK cascade
FGFR2, AR, BCAR3, BMP2, CD40, CD74, CDH2, CTNNB1, EFNA1, EGF, EGFR, ERBB2
 GO:0043410 85 / 224 3.8× 2.71e-29 1.41e-25 ✓ sig.
positive regulation of DNA-templated transcription
AHR, CHEK2, ESR1, ACVR1, AR, ARID1A, BIRC2, BMP2, BMP4, BRCA1, BRCA2, CD74
 GO:0045893 182 / 778 2.3× 4.02e-29 2.03e-25 ✓ sig.
response to xenobiotic stimulus
AHR, ABCB1, ABCC1, ABL1, ACACB, BCAR3, BCHE, BCL2, CAT, CCND1, CDH1, CENPF
 GO:0009410 87 / 248 3.5× 4.38e-27 1.93e-23 ✓ sig.
negative regulation of gene expression
ESR1, ADAM10, AKT1, AURKA, BMP2, BMP4, CTNNB1, CXCL8, DLL4, DNMT1, EZH2, FBXW7
 GO:0010629 101 / 339 3.0× 7.83e-25 2.61e-21 ✓ sig.
response to hypoxia
ABCB1, ANGPTL4, BIRC2, BMP2, CAT, CAV1, COMT, CPT1A, CXCL12, CXCR4, CYP1A1, DIO3
 GO:0001666 68 / 176 3.9× 3.28e-24 9.87e-21 ✓ sig.
positive regulation of apoptotic process
ABL1, ATM, BARD1, BAX, BCL2, BCL2A1, BMP2, BMP4, C1QBP, CASP8, CDKN2A, CTNNB1
 GO:0043065 97 / 326 3.0× 7.59e-24 2.19e-20 ✓ sig.
cell population proliferation
AKT1, BAP1, BAX, BCL2, BMP4, BRCA2, CAV1, CCND1, CSF1R, CSF2, CTNNB1, EGF
 GO:0008283 84 / 263 3.2× 4.69e-23 1.19e-19 ✓ sig.

Pairs within this cluster, by significance

Disease A ⇵ Disease B ⇵ Similarity score ⇵ Shared genes ⇵ P-value ⇵ FDR q-value ⇵
Breast neoplasms Prostatic neoplasms 0.110 113 8.25e-52 4.45e-50 ✓ sig.
Breast neoplasms Lung neoplasms 0.097 68 1.96e-42 8.62e-41 ✓ sig.
Lung neoplasms Prostatic neoplasms 0.088 71 5.91e-40 2.47e-38 ✓ sig.
Prostatic neoplasms Urinary bladder neoplasms 0.077 55 1.29e-39 5.36e-38 ✓ sig.
Breast neoplasms Non-small-cell lung carcinoma 0.082 50 8.17e-38 3.21e-36 ✓ sig.
Breast neoplasms Urinary bladder neoplasms 0.080 49 1.39e-36 5.35e-35 ✓ sig.
Breast neoplasms Stomach neoplasms 0.089 67 7.65e-36 2.86e-34 ✓ sig.
Lung neoplasms Stomach neoplasms 0.098 50 1.41e-35 5.18e-34 ✓ sig.
Prostatic neoplasms Stomach neoplasms 0.081 70 2.83e-33 9.67e-32 ✓ sig.
Lung neoplasms Non-small-cell lung carcinoma 0.094 34 3.82e-30 1.17e-28 ✓ sig.
Liver neoplasms Lung neoplasms 0.082 31 2.96e-25 7.33e-24 ✓ sig.
Breast neoplasms Liver neoplasms 0.062 39 6.94e-24 1.58e-22 ✓ sig.
Breast neoplasms Mesothelioma 0.061 38 1.16e-23 2.63e-22 ✓ sig.
Lung neoplasms Mesothelioma 0.070 26 7.83e-20 1.48e-18 ✓ sig.
Non-small-cell lung carcinoma Urinary bladder neoplasms 0.080 21 1.02e-19 1.92e-18 ✓ sig.
Urinary bladder neoplasms Uterine neoplasms 0.084 14 1.34e-19 2.50e-18 ✓ sig.
Non-small-cell lung carcinoma Uterine neoplasms 0.084 14 1.34e-19 2.50e-18 ✓ sig.
Carcinoma Stomach neoplasms 0.065 29 1.78e-19 3.27e-18 ✓ sig.
Carcinoma Lung neoplasms 0.069 27 1.79e-19 3.29e-18 ✓ sig.
Liver neoplasms Non-small-cell lung carcinoma 0.073 20 8.69e-18 1.47e-16 ✓ sig.
Carcinoma Urinary bladder neoplasms 0.066 19 7.64e-16 1.15e-14 ✓ sig.
Neuroblastoma Urinary bladder neoplasms 0.054 15 8.69e-12 9.59e-11 ✓ sig.
Liver neoplasms Neuroblastoma 0.048 14 2.82e-10 2.69e-9 ✓ sig.
Neuroblastoma Stomach neoplasms 0.041 18 1.19e-9 1.07e-8 ✓ sig.
Colobomatous macrophthalmia microcornea syndrome Neuroblastoma 0.007 1 9.81e-3 1.11e-2 ✓ sig.
Liver neoplasms Pulmonary agenesis 0.007 1 9.87e-3 1.12e-2 ✓ sig.
Liver neoplasms Retinitis pigmentosa, hearing loss, premature aging, short stature, facial dysmorphism syndrome 0.007 1 9.87e-3 1.12e-2 ✓ sig.
Lung neoplasms Pulmonary agenesis 0.004 1 1.65e-2 1.81e-2 ✓ sig.
Cerebellar ataxia, brain abnormalities, and cardiac conduction defects Stomach neoplasms 0.003 1 1.99e-2 2.16e-2 ✓ sig.
Isobutyryl-coa dehydrogenase deficiency Stomach neoplasms 0.003 1 1.99e-2 2.16e-2 ✓ sig.
Breast neoplasms Diffuse lymphatic malformation 0.002 1 3.36e-2 3.55e-2 ✓ sig.
Breast neoplasms Hypotrichosis and recurrent skin vesicles 0.002 1 3.36e-2 3.55e-2 ✓ sig.
Intellectual developmental disorder seizures polymicrogyria Prostatic neoplasms 0.002 1 4.07e-2 4.26e-2 ✓ sig.